Article: Imatinib mesylate can help to direct natural immunity toward an anti-leukemic reactivity by acting on the bone marrow microenvironment

We discuss our recent findings on the increase, in chronic myeloid leukemia patients treated with imatinib, of B1 lymphocytes producing IgM anti-O-linked sugars expressed by leukemic cells, paralleled by increased B-stimulating cytokines. We propose that one important effect of imatinib treatment is due to the remodelling of bone marrow microenvironment.

Citing Articles

Immunoglubolin dynamics and cancer prevalence in Tasmanian devils (Sarcophilus harrisii).

Ujvari B, Hamede R, Peck S, Pemberton D, Jones M, Belov K Sci Rep. 2016; 6:25093.

PMID: 27126067 PMC: 4850387. DOI: 10.1038/srep25093.

Assessment of interleukin 1β serum level in different responder groups and stages of chronic myeloid leukemia patients on imatinb mesylate therapy.

Matti B, Saleem M, Sabir S Indian J Hematol Blood Transfus. 2014; 30(4):247-52.

PMID: 25435722 PMC: 4243414. DOI: 10.1007/s12288-014-0339-7.

Dasatinib promotes Th1-type responses in granzyme B expressing T-cells.

Kreutzman A, Ilander M, Porkka K, Vakkila J, Mustjoki S Oncoimmunology. 2014; 3:e28925.

PMID: 25083322 PMC: 4106168. DOI: 10.4161/onci.28925.

Current trends of anticancer immunochemotherapy.

Vacchelli E, Prada N, Kepp O, Galluzzi L Oncoimmunology. 2013; 2(6):e25396.

PMID: 23894726 PMC: 3716761. DOI: 10.4161/onci.25396.

References

1.

Smyth M . Imatinib mesylate--uncovering a fast track to adaptive immunity. N Engl J Med. 2006; 354(21):2282-4. DOI: 10.1056/NEJMcibr061878. View

2.

Martin F, Kearney J . B1 cells: similarities and differences with other B cell subsets. Curr Opin Immunol. 2001; 13(2):195-201. DOI: 10.1016/s0952-7915(00)00204-1. View

3.

Schwartz-Albiez R, Laban S, Eichmuller S, Kirschfink M . Cytotoxic natural antibodies against human tumours: an option for anti-cancer immunotherapy?. Autoimmun Rev. 2008; 7(6):491-5. DOI: 10.1016/j.autrev.2008.03.012. View

4.

Tibullo D, Giallongo C, La Cava P, Berretta S, Stagno F, Chiarenza A . Effects of imatinib mesylate in osteoblastogenesis. Exp Hematol. 2009; 37(4):461-8. DOI: 10.1016/j.exphem.2008.12.008. View

5.

Schaumann D, Tuischer J, Ebell W, Manz R, Lauster R . VCAM-1-positive stromal cells from human bone marrow producing cytokines for B lineage progenitors and for plasma cells: SDF-1, flt3L, and BAFF. Mol Immunol. 2006; 44(7):1606-12. DOI: 10.1016/j.molimm.2006.08.021. View

6.

Catellani S, Pierri I, Gobbi M, Poggi A, Zocchi M . Imatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemia. PLoS One. 2011; 6(4):e18925. PMC: 3078937. DOI: 10.1371/journal.pone.0018925. View

7.

Holtz M, Slovak M, Zhang F, Sawyers C, Forman S, Bhatia R . Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood. 2002; 99(10):3792-800. DOI: 10.1182/blood.v99.10.3792. View

8.

Durig J, Rosenthal C, Elmaagacli A, Heyworth C, Halfmeyer K, Kasper C . Biological effects of stroma-derived factor-1 alpha on normal and CML CD34+ haemopoietic cells. Leukemia. 2000; 14(9):1652-60. DOI: 10.1038/sj.leu.2401875. View

9.

Hochhaus A, OBrien S, Guilhot F, Druker B, Branford S, Foroni L . Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009; 23(6):1054-61. DOI: 10.1038/leu.2009.38. View

10.

Apperley J . Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007; 8(11):1018-29. DOI: 10.1016/S1470-2045(07)70342-X. View

Imatinib Mesylate Can Help to Direct Natural Immunity Toward an Anti-leukemic Reactivity by Acting on the Bone Marrow Microenvironment